Fortitude Family Office’s Arcturus Therapeutics ARCT Stock Holding History

Fortitude Family Office’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$900	Buy	+134	New	+$1.06K	﹤0.01%	1785

Other funds holding ARCT

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

Fortitude Family Office's ARCT Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Arcturus Therapeutics (ARCT) in Q2 2026: 134 shares worth $900. The stake represents ﹤0.01% of the portfolio and ranks #1785 among its holdings.

20 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Fortitude Family Office held 134 shares of Arcturus Therapeutics worth $900 as of Q2 2026.
Arcturus Therapeutics was a new Fortitude Family Office position in Q2 2026.
Arcturus Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1785 holding.
20 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.